ClinicaliQ Trial Snapshot
- Hydra Registry – UK — Recruiting • Cardiology / Cardiovascular • NCT06507579.
- What is being tested: Efficacy and safety of the Hydra transcatheter aortic heart valve (THV) series for transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis, with follow-up evaluation extending to 1 year post-procedure.
- Patient eligibility overview: The registry includes patients with severe aortic stenosis who are suitable candidates for TAVI, with assessment criteria determining their eligibility for this minimally invasive intervention.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The study will evaluate the efficacy and safety of transcatheter aortic valve implantation (TAVI) using the Hydra transcatheter aortic heart valve (THV) series, in patients with severe aortic stenosis up to 1-year after the procedure. This will include an evaluation of the preservation of coronary access post implant by attempting to selectively engage both the right and left coronary arteries through standardised angiographic views. The study will also examine the utility of 72 hours of post discharge remote ambulatory continuous electrocardiogram (ECG) monitoring using the novel Checkpoint Cardio System where…
Eligibility Snapshot
- : 1. Patients with severe aortic stenosis eligible for transfemoral TAVI procedure as per local Heart Team evaluation 2. Full understanding and willing to provide informed consent to study enrolment 3. Age ≥ 18 years
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.